Chemical Biology Screening Identifies a Vulnerability to Checkpoint Kinase Inhibitors in TSC2-Deficient Renal Angiomyolipomas.
AZD7762
CHEK1/2
Chk1/2
TSC2
checkpoint kinase inhibitors
mTOR
tuberous sclerosis complex
tumor xenografts
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
11
01
2022
accepted:
14
02
2022
entrez:
1
4
2022
pubmed:
2
4
2022
medline:
2
4
2022
Statut:
epublish
Résumé
The tuberous sclerosis complex (TSC) is a rare genetic syndrome and multisystem disease resulting in tumor formation in major organs. A molecular hallmark of TSC is a dysregulation of the mammalian target of rapamycin (mTOR) through loss-of-function mutations in either tumor suppressor
Identifiants
pubmed: 35359406
doi: 10.3389/fonc.2022.852859
pmc: PMC8960247
doi:
Types de publication
Journal Article
Langues
eng
Pagination
852859Subventions
Organisme : NCI NIH HHS
ID : K00 CA245821
Pays : United States
Organisme : NCI NIH HHS
ID : R21 CA263133
Pays : United States
Informations de copyright
Copyright © 2022 Vaughan, Kordich, Chan, Sasi, Celano, Sisson, Van Baren, Kortus, Aguiar, Martin and MacKeigan.
Déclaration de conflit d'intérêts
JM has consulting agreements with Merck, research support from Erasca, and scholarly activity and support from Translational Genomics Research Institute (non-profit organization). JK’s current affiliation is with AbbVie. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Am J Hum Genet. 2007 Apr;80(4):588-604
pubmed: 17357067
Nat Commun. 2016 Feb 12;7:10662
pubmed: 26868506
Mol Cancer Ther. 2008 Sep;7(9):2955-66
pubmed: 18790776
Mol Cell. 2008 Jun 20;30(6):701-11
pubmed: 18570873
N Engl J Med. 2011 Apr 28;364(17):1595-606
pubmed: 21410393
Lancet. 2013 Jan 12;381(9861):125-32
pubmed: 23158522
Invest New Drugs. 2014 Apr;32(2):213-26
pubmed: 24114124
Mol Cancer Res. 2014 Jan;12(1):48-57
pubmed: 24296756
Sci Rep. 2019 Feb 28;9(1):3015
pubmed: 30816188
Biochim Biophys Acta Mol Cell Res. 2018 Sep;1865(9):1293-1311
pubmed: 29936127
Nat Cell Biol. 2002 Sep;4(9):648-57
pubmed: 12172553
Neurology. 2013 Feb 5;80(6):574-80
pubmed: 23325902
Nat Commun. 2017 Jun 15;8:15816
pubmed: 28643795
Mol Med. 2007 Mar-Apr;13(3-4):160-5
pubmed: 17592550
JCI Insight. 2018 Apr 19;3(8):
pubmed: 29669930
Nat Protoc. 2013 Nov;8(11):2240-55
pubmed: 24136348
Nat Cell Biol. 2018 Mar;20(3):320-331
pubmed: 29403037
Nat Methods. 2015 May;12(5):453-7
pubmed: 25822800
Am J Physiol Lung Cell Mol Physiol. 2004 Apr;286(4):L694-700
pubmed: 12922981
J Clin Invest. 2003 Oct;112(8):1223-33
pubmed: 14561707
Cancer Chemother Pharmacol. 2014 Mar;73(3):539-49
pubmed: 24448638
J Transl Med. 2010 Feb 10;8:14
pubmed: 20146790
PLoS Genet. 2015 Nov 05;11(11):e1005637
pubmed: 26540169
Am J Hum Genet. 2001 Jan;68(1):64-80
pubmed: 11112665
N Engl J Med. 2006 Sep 28;355(13):1345-56
pubmed: 17005952
Mol Cell Biol. 2017 Feb 15;37(5):
pubmed: 27956700
Am J Kidney Dis. 2015 Oct;66(4):638-45
pubmed: 26165440
Pediatr Nephrol. 2017 Jul;32(7):1137-1144
pubmed: 27585680
N Engl J Med. 2008 Jan 10;358(2):140-51
pubmed: 18184959
N Engl J Med. 2010 Nov 4;363(19):1801-11
pubmed: 21047224
Neuro Oncol. 2015 Dec;17(12):1550-9
pubmed: 26289591